Mogamulizumab Phase III CTCL program expanded to Japan
This article was originally published in Scrip
Kyowa Hakko Kirin has added sites in Japan to the ongoing multinational Phase III clinical trial with its lead antibody mogamulizumab for cutaneous T-cell lymphoma (CTCL), firming up the likelihood of an approval submission in this market for the indication.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.